Molecule intelOpportunity: Lower0

Imipenem

28 brands · 21 companies · product forms

1 DRAP alert

Opportunity snapshot

Launch attractiveness
33
Market saturation
55
Price room
100
Regulatory risk
50
28
brands
21
companies
Rs 1,455.12
median price
19
price points
7.35x
price spread
90
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 11%

Price room

Across observed sources and strengths
CheapestRs 251.26
MedianRs 1,455.12
Most expensiveRs 1,846.42
Spread7.35×
Sources: DRAP-official, DVAGO, Servaid

max/min price ratio 7.35x across 19 trusted points (Rs 251.26-1846.42). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 2 live products for Imipenem — each links to its own medicine page.

Regulatory alerts

Safety exposurelatest 2023-02-27
Rapid Alert: Falsified / Spurious Cilapen 500mg Injection identified in the market

Why this score

Launch attractiveness

40% supply-gap(0) + 25% price-variation(100) + 20% low-competition(45) + 15% supply-disruption(0), damped by confidence(90). Higher = more attractive, less crowded opportunity.

Market saturation

21 canonical companies and 28 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 7.35x across 19 trusted points (Rs 251.26-1846.42). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

1 DRAP alert(s), latest 2023-02-27 incl. recall/safety.

Confidence

Reduced by: no ATC code.

Packaged brief for this lower opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.